Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714800 | 0.86 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1ELANETSHRMEN1 | |
| SCHEMBL1638661 | 0.77 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1ELANETSHRHTT | |
| SCHEMBL10531540 | 0.77 | NAMPT (0.37) | ALDH1A1ELANEMEN1KMT2AADORA2B | |
| SCHEMBL20552850 | 0.77 | L3MBTL1 (0.63) | L3MBTL1PDE10AALDH1A1TSHRHTT | |
| SCHEMBL27714795 | 0.76 | CYP3A4 (0.39) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10339810 | 0.76 | RET (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL9876682 | 0.74 | GSK3B (0.43) | ALDH1A1 | |
| SCHEMBL13562830 | 0.74 | L3MBTL1 (0.67) | L3MBTL1PDE10ATSHRHTTSMN1; SMN2 | |
| SCHEMBL25757542 | 0.72 | L3MBTL1 (0.60) | L3MBTL1PDE10AALDH1A1TSHRHTT | |
| SCHEMBL14578720 | 0.70 | MTNR1A (0.64) | ALDH1A1CNR1CNR2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155203-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-1906965-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7777035-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | L3MBTL1 2451/4885PDE10A 1596/4885ALDH1A1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.